Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches.

× No keyword cloud information.

60 in total

1. Thermodynamics of protein destabilization in live cells.

Authors: Jens Danielsson; Xin Mu; Lisa Lang; Huabing Wang; Andres Binolfi; François-Xavier Theillet; Beata Bekei; Derek T Logan; Philipp Selenko; Håkan Wennerström; Mikael Oliveberg
Journal: Proc Natl Acad Sci U S A Date: 2015-09-21 Impact factor: 11.205

2. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.

Authors: H Hamada; T Tsuruo
Journal: Proc Natl Acad Sci U S A Date: 1986-10 Impact factor: 11.205

3. Growth of normal human ovarian surface epithelial cells in reduced-serum and serum-free media.

Authors: W M Elliott; N Auersperg
Journal: In Vitro Cell Dev Biol Date: 1993-01

4. Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.

Authors: Ashley Browne; Laura A Tookman; Carin K Ingemarsdotter; Russell D Bouwman; Katrina Pirlo; Yaohe Wang; Iain A McNeish; Michelle Lockley
Journal: Cancer Res Date: 2015-05-14 Impact factor: 12.701

5. CD44 and beta1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins.

Authors: R C Casey; A P Skubitz
Journal: Clin Exp Metastasis Date: 2000 Impact factor: 5.150

6. High expression of integrin αvβ3 enables uptake of targeted fluorescent probes into ovarian cancer cells and tumors.

Authors: Scott K Shaw; Cynthia L Schreiber; Felicia M Roland; Paul M Battles; Seamus P Brennan; Simon J Padanilam; Bradley D Smith
Journal: Bioorg Med Chem Date: 2018-03-06 Impact factor: 3.641

7. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers.

Authors: A Sharma; N L Straubinger; R M Straubinger
Journal: Pharm Res Date: 1993-10 Impact factor: 4.200

8. Establishment of an in vitro assay to measure the invasion of ovarian carcinoma cells through mesothelial cell monolayers.

Authors: Rachael C Casey; Kimberly A Koch; Theodore R Oegema; Keith M Skubitz; Stefan E Pambuccian; Suzanne M Grindle; Amy P N Skubitz
Journal: Clin Exp Metastasis Date: 2003 Impact factor: 5.150

9. BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.

Authors: J M Day; P A Foster; H J Tutill; S P Newman; Y T Ho; M P Leese; B V L Potter; M J Reed; A Purohit
Journal: Br J Cancer Date: 2009-01-20 Impact factor: 7.640

10. In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring.

Authors: W Zhong; J P Celli; I Rizvi; Z Mai; B Q Spring; S H Yun; T Hasan
Journal: Br J Cancer Date: 2009-11-17 Impact factor: 7.640